Neurosense Therapeutics Ltd (NRSN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Neurosense Therapeutics Ltd (NRSN) has a cash flow conversion efficiency ratio of 0.004x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.00K) by net assets ($-519.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Neurosense Therapeutics Ltd defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Neurosense Therapeutics Ltd - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Neurosense Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Neurosense Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Neurosense Therapeutics Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SPECO Ltd
KQ:013810
|
0.064x |
|
Gotland Rederi AB Series B
ST:GOTL-B
|
-0.015x |
|
Modular Medical Inc
NASDAQ:MODD
|
-1.217x |
|
Paru Co. Ltd
KQ:043200
|
-0.010x |
|
OB Holdings Berhad
KLSE:0327
|
-0.040x |
|
Getabec Public Company Limited
BK:GTB
|
-0.045x |
|
Acroud AB
ST:ACROUD
|
0.062x |
|
Rex Industry Bhd
KLSE:9946
|
-0.129x |
Annual Cash Flow Conversion Efficiency for Neurosense Therapeutics Ltd (2019–2024)
The table below shows the annual cash flow conversion efficiency of Neurosense Therapeutics Ltd from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see Neurosense Therapeutics Ltd (NRSN) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $2.58 Million | $-10.13 Million | -3.924x | -183.04% |
| 2023-12-31 | $-1.77 Million | $-8.35 Million | 4.725x | +449.99% |
| 2022-12-31 | $5.62 Million | $-7.59 Million | -1.350x | -690.04% |
| 2021-12-31 | $9.01 Million | $-1.54 Million | -0.171x | +83.80% |
| 2020-12-31 | $659.00K | $-695.00K | -1.055x | -66.35% |
| 2019-12-31 | $918.00K | $-582.00K | -0.634x | -- |
About Neurosense Therapeutics Ltd
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical… Read more